Literature DB >> 21996439

Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer.

Qiao Ming Zhi1, Xue Hua Chen, Jun Ji, Jia Nian Zhang, Jian Fang Li, Qu Cai, Bing Ya Liu, Qin Long Gu, Zheng Gang Zhu, Ying Yan Yu.   

Abstract

Salinomycin is a novel identified cancer stem cells (CSCs) killer. Higher ALDH activity represents CSCs characterization. Here, we screened ALDH activities on several gastric cancer cell lines and divided them into ALDH(high) and ALDH(low) gastric cancer groups. ALDH(high) cancer cells (NCI-N87 and SNU-1) disclosed more CSCs characteristics, such as higher levels of Sox2, Nanog and Nestin, more floating spheroid bodies, more colony formation and more resistance to conventional chemotherapeutic drugs 5-Fu and CDDP, compared to these parameters observed in ALDH(low) cancer cells (P<0.01). Importantly, ALDH(high) cancer cells are relatively sensitive to salinomycin when compared to ALDH(low) cancer cells (P<0.01). Our results confirmed ALDH as functional marker of CSCs population on gastric cancer. Salinomycin might be selective therapy for CSCs fraction, which is resistant to conventional anticancer drugs 5-Fu and CDDP. Copyright Â
© 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21996439     DOI: 10.1016/j.biopha.2011.06.006

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  44 in total

Review 1.  Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review.

Authors:  Miguel Angel Chiurillo
Journal:  World J Exp Med       Date:  2015-05-20

Review 2.  p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy.

Authors:  Christie Rodriguez-Ramirez; Jacques E Nör
Journal:  Crit Rev Oncog       Date:  2018

Review 3.  Gastric cancer stem cells: evidence, potential markers, and clinical implications.

Authors:  Daniel Brungs; Morteza Aghmesheh; Kara L Vine; Therese M Becker; Martin G Carolan; Marie Ranson
Journal:  J Gastroenterol       Date:  2015-10-01       Impact factor: 7.527

Review 4.  Stem cells in gastrointestinal cancers: The road less travelled.

Authors:  Sameh Mikhail; Amer Zeidan
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

Review 5.  The Valley of Death in anticancer drug development: a reassessment.

Authors:  David J Adams
Journal:  Trends Pharmacol Sci       Date:  2012-03-10       Impact factor: 14.819

6.  Induction of G1 Cell Cycle Arrest in Human Glioma Cells by Salinomycin Through Triggering ROS-Mediated DNA Damage In Vitro and In Vivo.

Authors:  Shi-Jun Zhao; Xian-Jun Wang; Qing-Jian Wu; Chao Liu; Da-Wei Li; Xiao-Ting Fu; Hui-Fang Zhang; Lu-Rong Shao; Jing-Yi Sun; Bao-Liang Sun; Jing Zhai; Cun-Dong Fan
Journal:  Neurochem Res       Date:  2016-12-19       Impact factor: 3.996

Review 7.  Gastric cancer stem cells: a novel therapeutic target.

Authors:  Shree Ram Singh
Journal:  Cancer Lett       Date:  2013-04-10       Impact factor: 8.679

Review 8.  Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?

Authors:  Qian Zhang; Yunjiang Feng; Derek Kennedy
Journal:  Cell Mol Life Sci       Date:  2016-09-12       Impact factor: 9.261

9.  EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter.

Authors:  Lilian E van Vlerken; Christine M Kiefer; Chris Morehouse; Ying Li; Chris Groves; Susan D Wilson; Yihong Yao; Robert E Hollingsworth; Elaine M Hurt
Journal:  Stem Cells Transl Med       Date:  2012-12-27       Impact factor: 6.940

10.  Salinomycin efficiency assessment in non-tumor (HB4a) and tumor (MCF-7) human breast cells.

Authors:  Andressa Megumi Niwa; Gláucia Fernanda Rocha D Epiro; Lilian Areal Marques; Simone Cristine Semprebon; Daniele Sartori; Lúcia Regina Ribeiro; Mário Sérgio Mantovani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-03-02       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.